44 research outputs found
Indicateurs Smart Region
11. Sustainable cities and communitie
Webinaire - Jumeau Numériques: outils pour la gestion de crise sur les territoires?
REACT-EU FEDER11. Sustainable cities and communitie
Performance measurement in Smart Cities: an introductory report
ong the different debates surrounding Smart Cities, the topic of performance measurement has gained momentum. Several authors (e.g. Giffinger, 2007) and projects (e.g. CityKeys1) have provided frameworks for municipalities to measure and monitor their Smart City performance. While these frameworks are useful and interesting, they often measure the performance of a city with an outside-in approach. This implies that performance is often measured based on pre-defined sets of indicators, which is an asset for comparing territories. In this report, we focus on a more managerial approach – also called an inside-out approach. We aim to guide municipalities to define their own performance
measurement system that will allow them to improve their objectives and processes. Hence, we hereby propose an integrative model that is directly derived from the territory’s specificities. The model is constructed using an inductive approach built upon the existing literature on business performance management, public performance management and Smart City performance measurement & management. Note that, given the complexity of performance measurement, this report is only an introductory document. Therefore, the content is not exhaustive and will be completed in future publications from the Smart City Institute
Introduction to Smart Mobility
REACT EU - FEDER11. Sustainable cities and communitie
Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma
Objectives The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. Methods Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. Results On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P = 0.0455) and T215Y (P = 0.0455). Conclusions In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performe